{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:42:15Z","timestamp":1790743335397,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T00:00:00Z","timestamp":1532476800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s13318-018-0497-3","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T10:16:33Z","timestamp":1532513793000},"page":"637-644","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Clinical Pharmacokinetics and Drug Interactions of Doravirine"],"prefix":"10.1007","volume":"43","author":[{"given":"Kyle John","family":"Wilby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesma Ahmed","family":"Eissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,25]]},"reference":[{"key":"497_CR1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services. 2018. http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf . Accessed 28 May 2018."},{"key":"497_CR2","unstructured":"UNAIDS. The Global HIV\/AIDS Epidemic. U.S. Department of Health and Human Services. https:\/\/www.hiv.gov\/hiv-basics\/overview\/data-and-trends\/global-statistics . 2017. Accessed 28 May 2018."},{"issue":"1","key":"497_CR3","doi-asserted-by":"publisher","first-page":"18567","DOI":"10.7448\/IAS.16.1.18567","volume":"16","author":"I Usach","year":"2013","unstructured":"Usach I, Melis V, Peris J. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc. 2013;16(1):18567.","journal-title":"J Int AIDS Soc."},{"issue":"5","key":"497_CR4","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","volume":"5","author":"J Molina","year":"2018","unstructured":"Molina J, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-na\u00efve adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018;5(5):e211\u201320.","journal-title":"Lancet HIV"},{"key":"497_CR5","unstructured":"Squires KE, Molina J, Sax PE, Wong W, Orkin C, Sussmann O, et al. Fixed dose combination of doravirine\/lamivudine\/TDF is non-inferior to efavirenz\/emtricitabine\/TDF in treatment-na\u00efve adults with HIV-1 infection: week 48 results of the new Phase 3 DRIVE-AHEAD study. IAS 2017. http:\/\/programme.ias2017.org\/Abstract\/Abstract\/5585 . Accessed 28 May 2018."},{"issue":"4","key":"497_CR6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3851\/IMP2920","volume":"20","author":"M Anderson","year":"2015","unstructured":"Anderson M, Gilmartin J, Cilissen C, De Lepeleire I, Van Bortel L, Dockendorf MF, et al. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir Ther. 2015;20(4):397\u2013405.","journal-title":"Antivir Ther."},{"key":"497_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2018.1451667","author":"R Sanchez","year":"2018","unstructured":"Sanchez R, Fillgrove K, Yee K, Liang Y, Lu B, Tatavarti A, et al. Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans. Xenobiotica. 2018. https:\/\/doi.org\/10.1080\/00498254.2018.1451667 .","journal-title":"Xenobiotica."},{"issue":"4","key":"497_CR8","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/COH.0000000000000471","volume":"13","author":"MA Colombier","year":"2018","unstructured":"Colombier MA, Molina JM. Doravirine: a review. Curr Opin HIV AIDS. 2018;13(4):308\u201314.","journal-title":"Curr Opin HIV AIDS"},{"issue":"4","key":"497_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3851\/IMP3142","volume":"22","author":"M Behm","year":"2017","unstructured":"Behm M, Yee K, Fan L, Fackler P. Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects. Antivir Ther. 2017;22(4):337\u201344.","journal-title":"Antivir Ther."},{"issue":"6","key":"497_CR10","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40261-017-0512-5","volume":"37","author":"M Behm","year":"2017","unstructured":"Behm M, Yee K, Liu R, Levine V, Panebianco D, Fackler P. The effect of food on doravirine bioavailability: results from two pharmacokinetic studies in healthy subjects. Clin Drug Investig. 2017;37(6):571\u20139.","journal-title":"Clin Drug Investig."},{"issue":"6","key":"497_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/jcph.857","volume":"57","author":"S Khalilieh","year":"2016","unstructured":"Khalilieh S, Yee KL, Liu R, Fan L, Sanchez RI, Auger P, et al. Moderate hepatic impairment does not affect doravirine pharmacokinetics. J Clin Pharmacol. 2016;57(6):777\u201383.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"497_CR12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s40261-017-0513-4","volume":"37","author":"K Yee","year":"2017","unstructured":"Yee K, Khalilieh S, Sanchez R, Liu R, Anderson MS, Manthos H, et al. The effect of single and multiple doses of rifampin on the pharmacokinetics of doravirine in healthy subjects. Clin Drug Investig. 2017;37(7):659\u201367.","journal-title":"Clin Drug Investig."},{"key":"497_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1103","author":"S Khalilieh","year":"2018","unstructured":"Khalilieh S, Yee K, Sanchez R, Liu R, Fan L, Martell M, et al. Multiple doses of rifabutin reduce exposure of doravirine in healthy subjects. J Clin Pharmacol. 2018. https:\/\/doi.org\/10.1002\/jcph.1103 (early online).","journal-title":"J Clin Pharmacol."},{"key":"497_CR14","unstructured":"Khalilieh S, Anderson M, Laethem M, Yee K, Sanchez R, Fan L, et al. Multiple-dose treatment with ritonavir increases the exposure of doravirine. In: Conference on retroviruses and opportunistic infections. February 13\u201316, 2017. Seattle, WA. Abstract 412."},{"issue":"Suppl 1","key":"497_CR15","first-page":"73","volume":"48","author":"RI Sanchez","year":"2016","unstructured":"Sanchez RI, Filgrove K, Hafey M, Palamanda J, Newton D, Lu B, Bleasby K. In vitro evaluation of doravirine potential for pharmacokinetic drug interactions. Drug Metab Rev. 2016;48(Suppl 1):73.","journal-title":"Drug Metab Rev"},{"key":"497_CR16","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1086\/518655","volume":"196","author":"H McIlleron","year":"2007","unstructured":"McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Inf Dis. 2007;196:S63\u201375.","journal-title":"J Inf Dis"},{"issue":"11","key":"497_CR17","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.5588\/ijtld.11.0068","volume":"15","author":"DJ Horne","year":"2011","unstructured":"Horne DJ, Spitters C, Narita M. Experience with rifabutin replacing rifampin in the treatment of tuberculosis. Int J Tuberc Lung Dis. 2011;15(11):1485\u201390.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"497_CR18","doi-asserted-by":"publisher","first-page":"e01364-16","DOI":"10.1128\/AAC.01364-16","volume":"61","author":"S Khalilieh","year":"2016","unstructured":"Khalilieh S, Yee K, Sanchez R, Triantafyllou I, Fan L, Maklad N, et al. Results of a doravirine-atorvastatin drug\u2013drug interaction study. Antimicrob Agents Chemother. 2016;61(2):e01364-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"497_CR19","doi-asserted-by":"publisher","first-page":"e01757-16","DOI":"10.1128\/AAC.01757-16","volume":"61","author":"KL Yee","year":"2016","unstructured":"Yee KL, Sanchez R, Auger P, Liu R, Fan L, Triantafyllou I, et al. An evaluation of doravirine pharmacokinetics when switching from efavirenz to doravirine in healthy subjects. Antimicrob Agents Chemother. 2016;61(2):e01757-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"497_CR20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40262-016-0458-4","volume":"56","author":"M Anderson","year":"2016","unstructured":"Anderson M, Khalilieh S, Yee KL, Liu R, Fan L, Rizk ML, et al. A two-way steady-state pharmacokinetic interaction study of doravirine (MK-1439) and dolutegravir. Clin Pharmacokinet. 2016;56(6):661\u20139.","journal-title":"Clin Pharmacokinet"},{"key":"497_CR21","unstructured":"Ankrom W, Yee KL, Triantafyllou I, Fan L, Sanchez RI, Iwamoto M, Khalilieh S. Doravirine does not have a clinically meaningful pharmacokinetic interaction with ledipasvir\/sofosbuvir (HARVONI). In: 18th International workshop on clinical pharmacology of antiviral therapy. June 14\u201317, 2017. Chicago, IL. Abstract P_39."},{"key":"497_CR22","unstructured":"Ankrom W, Yee KL, Wolford D, Mitra PK, Fan L, Sanchez RI, et al. Doravirine does not have a clinically meaningful pharmacokinetic interaction with elbasvir plus grazoprevir. In: 18th International workshop on clinical pharmacology of antiviral therapy. June 14\u201317, 2017. Chicago, IL. Abstract P_42."},{"key":"497_CR23","doi-asserted-by":"crossref","unstructured":"Khalilieh S, Yee KL, Sanchez RI, Vaynshteyn K, Deschamps K, Fan L, et al. Co-administration of doravirine with an aluminum\/magnesium-containing antacid or pantoprazole, a proton-pump inhibitor, does not have a clinically meaningful effect on doravirine pharmacokinetics. IAS Conference on HIV Science. July 23-26, 2017. Paris, France.","DOI":"10.26226\/morressier.57ea3d6ad462b8028d88e972"},{"key":"497_CR24","unstructured":"Yee KL, Chatterjee M, Dockendorf M, Lai M, Teppler H, Rizk M, et al. Pharmacokinetics (PK) of doravirine and exposure-response analysis: efficacy and safety implications. In: Interscience conference on antimicrobial agents and chemotherapy, September 5\u20139, 2014. Washington, DC."},{"issue":"1","key":"497_CR25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/QAD.0000000000000876","volume":"30","author":"D Shurmann","year":"2016","unstructured":"Shurmann D, Sobotha C, Gilmartin J, Robberechts M, De Lepeleire I, Yee KL, et al. A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-na\u00efve HIV-infected individuals. AIDS. 2016;30(1):57\u201363.","journal-title":"AIDS"},{"issue":"10","key":"497_CR26","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s40261-017-0552-x","volume":"37","author":"SG Khalilieh","year":"2017","unstructured":"Khalilieh SG, Yee KL, Fan L, Liu R, Heber W, Dunzo E, et al. A randomized trial to assess the effect of doravirine on the QTc interval using a single supratherapeutic dose in healthy adult volunteers. Clin Drug Invest. 2017;37(10):975\u201384.","journal-title":"Clin Drug Invest."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-018-0497-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0497-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0497-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T04:47:22Z","timestamp":1661662042000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-018-0497-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,25]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["497"],"URL":"https:\/\/doi.org\/10.1007\/s13318-018-0497-3","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,25]]},"assertion":[{"value":"25 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Wilby and Dr. Eissa report no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"No funding was received for this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}